In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Precision BioSciences (DTIL – Research Report), with a price target of $34.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kostas Biliouris has given his Buy rating due to a combination of factors surrounding Precision BioSciences’s recent developments and potential. Firstly, the initial clinical data for PBGENE-HBV, an in vivo gene editing therapy targeting Hepatitis B, shows promising results with substantial HBsAg reduction in patients and a clean safety profile. This early success, despite being at a lower dose, suggests further efficacy might be achieved with higher or repeated dosing. Additionally, the underlying technology platform has been validated independently, which strengthens confidence in its potential.
Another critical reason for the Buy rating is the significant undervaluation of Precision BioSciences’s stock, trading at a fraction of its cash position. The company’s financial runway supports continued development and future readouts that could significantly enhance its market position. Furthermore, the positive implications of the PBGENE-HBV data on other programs, such as their mitochondrial myopathy treatment, add to the company’s appeal. Collectively, these elements indicate a favorable risk/reward scenario that justifies the Buy recommendation.
Biliouris covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and BioMarin Pharmaceutical. According to TipRanks, Biliouris has an average return of -8.9% and a 33.67% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.